BridgeMD
Pilot study comparing the efficacy of intra-articular glenohumeral injection combined with suprascapular nerve block versus intra-articular glenohumeral corticosteroid injection in adhesive capsulitis.
EU CTIS ID: 2026-525317-31-00
What this study is testing
Compare the improvement in shoulder function at 3 months between the intra-articular injection group combined with a suprascapular nerve block and the intra-articular injection group combined with a placebo block.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients with shoulder stiffness lasting at least 2 months and less than 12 months, with a loss of passive joint range of motion in at least 2 planes (lateral rotation, medial rotation, abduction, antepulsion) of at least 30 degrees compared to the contralateral side
- Patients aged between 18 and 65 years
- Patients affiliated with a social security system
You likely can't join if
- Corticosteroid injection in the affected shoulder < 4 months
- - Anticoagulation with VKA or anti-Xa, or bleeding disorder currently active or in remission for less than 5 years (malignant blood disorders, myelodysplasia, autoimmune thrombocytopenia) or chemotherapy (antiplatelet agents authorized except prasugrel and clopidogrel)*
- Uncontrolled high blood pressure,
- Uncontrolled diabetes or at risk of decompensation,
- Contraindications for diprosten, Kenacort, or lidocaine
- Persons belonging to a vulnerable group as defined by Regulation (EU) No. 536/2014 and French law
See the full eligibility criteria
- Patients with shoulder stiffness lasting at least 2 months and less than 12 months, with a loss of passive joint range of motion in at least 2 planes (lateral rotation, medial rotation, abduction, antepulsion) of at least 30 degrees compared to the contralateral side
- Patients aged between 18 and 65 years
- Patients affiliated with a social security system
- Corticosteroid injection in the affected shoulder < 4 months
- - Anticoagulation with VKA or anti-Xa, or bleeding disorder currently active or in remission for less than 5 years (malignant blood disorders, myelodysplasia, autoimmune thrombocytopenia) or chemotherapy (antiplatelet agents authorized except prasugrel and clopidogrel)*
- Uncontrolled high blood pressure,
- Uncontrolled diabetes or at risk of decompensation,
- Contraindications for diprosten, Kenacort, or lidocaine
- Persons belonging to a vulnerable group as defined by Regulation (EU) No. 536/2014 and French law
- Patients who are unable to comply with the protocol requirements
- Psychiatric condition likely to be decompensated by corticosteroids
- Women who are pregnant or breastfeeding or who refuse effective contraception
- Patients participating in another clinical research protocol involving a drug or medical device
- Patients refusing to participate in the study
- History of any surgery on the affected shoulder within the last 12 months
- Patients with neuromuscular disorders (neurological deficits) or shoulder disorders (arthropathy) that could interfere with the assessment of the primary endpoint
- Signs or risks of infection (bacterial infection and/or fever and/or antibiotic use)
- Poor skin condition of the pathological shoulder
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.